Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
December 19, 2025
Foley Viewpoints
Prohibition to Prescription: What Trump’s Marijuana Executive Order Really Means
On December 18, 2025, President Donald Trump issued an Executive Order, Increasing Medical Marijuana and Cannabidiol Research, that…
December 18, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 18, 2025
Innovative Technology Insights
Data Centers: The Role of AI and Semiconductors in Transforming an Industry
Data Centers: The Role of AI and Semiconductors in Transforming an Industry Key Takeaways AI is driving unprecedented demand for data…